Zenas BioPharma ZBIO announced that the phase III INDIGO study, which evaluated its lead pipeline candidate, obexelimab, for treating patients with immunoglobulin G4-related disease (IgG4-RD), has met ...
Late-breaking analysis from pivotal INDIGO Phase 3 trial demonstrates vorasidenib led to tumor shrinkage in IDH1/2-mutant diffuse glioma First data from Phase 1 trial show the safety and tolerability ...
Indigo is a cornerstone of denim production, yet its environmental impact remains shrouded in mystery—even within the industry itself. A new report from the Transformers Foundation called “A Reference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results